From Risk to Resilience: The IMPACT Peanut Study

Peanut allergy can make everyday life stressful — from birthday parties to school snacks. But what if there was a way to help children build protection instead of just avoiding peanuts altogether? 

In this episode, we dive into the Immune Tolerance Network IMPACT trial, a groundbreaking study testing whether tiny, carefully measured doses of peanut protein could help young children live with less fear and more freedom. We’ll break down what the research found, what it means for families right now, and where peanut allergy treatment might be headed next.

Sources:

• Jones, et al. (2022) Efficacy and safety of oral immunotherapy in children aged 1–3 years with peanut allergy (the Immune Tolerance Network IMPACT trial): a randomised placebo-controlled study. Lancet, 399, pp.359–371.
• Virkud, et al. (2025) Long-Term Assessment of Antibody Profiles after the IMPACT Peanut Oral Immunotherapy Trial: Findings from the IMPACT-PLuS Follow-up. J ALLERGY CLIN IMMUNOL, February, AB444 Abstracts, L49.
• Dantzer, et al. (2024) Long-Term Follow-up after IMPACT Peanut Oral Immunotherapy Clinical Trial. J ALLERGY CLIN IMMUNOL, February, AB240 Abstracts, 742.

Disclaimer: The information shared in this podcast and on this website is not intended to replace professional medical advice, diagnosis, or treatment. Always consult your doctor or a qualified healthcare provider with any questions you may have about a medical condition. Please don't ignore or delay seeking medical advice based on content from this podcast or website.

Buy me a coffee: https://coff.ee/goodlifecreations

Chapters

• 0:00 Tempo: 120.0